Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 42

Sort by

Sort Order Select

Journal Articles

Low Expression of ROR1 on Chronic Lymphocytic Leukemia Is Associated with Other Atypical Findings

H. Elizabeth Broome, MD, Laura Z. Rassenti, Ph.D., Michael Y. Choi, MD, Thomas J. Kipps, M.D., Ph.D

Blood (2011) 118 (21): 4588.

https://doi.org/10.1182/blood.V118.21.4588.4588

Published: 2011

Journal Articles

Variation in Health-Related Quality of Life by ECOG Performance Status and Fatigue Among Patients with Chronic Lymphocytic Leukemia

Chris L. Pashos, PhD, Christopher R Flowers, MD, Mark Weiss, MD, Nicole Lamanna, MD, Charles M Farber, MD, PhD, Thomas J. Kipps, M.D., Ph.D, Susan Lerner, MS, BA, Neil Kay, MD, Jeff Porte Sharman, MD, David L. Grinblatt, MD, Ian W. Flinn, MD, PhD, Mark Kozloff, MD, Arlene S Swern, PhD, Zeba M. Kahn, Ph.D, Thomas K. Street, RPh, Gale Harding, MA, Kristen A Sullivan, MBA, Michael J Keating, MD

Blood (2011) 118 (21): 4591.

https://doi.org/10.1182/blood.V118.21.4591.4591

Published: 2011

Journal Articles

Variation in Health-Related Quality of Life by Age Among Patients with Chronic Lymphocytic Leukemia

Chris L. Pashos, PhD, Christopher R Flowers, MD, Mark Weiss, MD, Nicole Lamanna, MD, Charles M Farber, MD, PhD, Thomas J. Kipps, M.D., Ph.D, Susan Lerner, MS, BA, Neil Kay, MD, Jeff Porte Sharman, MD, David L. Grinblatt, MD, Ian W. Flinn, MD, PhD, Mark Kozloff, MD, Arlene S Swern, PhD, Zeba M. Kahn, Ph.D, Thomas K. Street, RPh, Kristen A Sullivan, MBA, Gale Harding, MA, Michael J Keating, MD

Blood (2011) 118 (21): 2085.

https://doi.org/10.1182/blood.V118.21.2085.2085

Published: 2011

Journal Articles

Navitoclax (ABT-263) Plus Fludarabine/Cyclophosphamide/Rituximab (FCR) or Bendamustine/Rituximab (BR): A Phase 1 Study in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL),

Thomas J. Kipps, M.D., Ph.D, Lode J. Swinnen, MD, William G. Wierda, MD, PhD, Jeffrey Alan Jones, MD, MPH, Steven E. Coutre, MD, Mitchell R Smith, MD, PhD, Jianning Yang, PhD, Yue Cui, PhD, Todd Busman, MS, Sari Enschede, MD, Rod Humerickhouse, MD

Blood (2011) 118 (21): 3904.

https://doi.org/10.1182/blood.V118.21.3904.3904

Published: 2011

Journal Articles

ROR1 Expression Accelerates Leukemia Development in RORxTCL1 Transgenic Mice,

George F. Widhopf, II, PhD, Bing Cui, Ph.D., Esther Avery, B.S., George Chen, B.S., Masato Obara, MD, PhD, Karen Messer, PhD, Thomas J. Kipps, M.D., Ph.D

Blood (2011) 118 (21): 3905.

https://doi.org/10.1182/blood.V118.21.3905.3905

Published: 2011

Journal Articles

Mir-155 Contributed to Chronic Lymphocytic Leukemia Survival by Modulation of BCR-Signalling

Liguang Chen, MD, PhD, Bing Cui, PhD, George Chen, B.S., Michelle Salcedo, BS, Carlo M. Croce, MD, Thomas J. Kipps, M.D., Ph.D

Blood (2011) 118 (21): 620.

https://doi.org/10.1182/blood.V118.21.620.620

Published: 2011

Journal Articles

A Monoclonal Antibody Specifically Targeting CD44 Inhibits B-Cell Chronic Lymphocytic Leukemia Cell Survival In Vitro and In Vivo

Suping Zhang, PhD, Christina C.N. Wu, Ph.D., Jessie-Farah Fecteau, Ph.D., Bing Cui, PhD, Rongrong Wu, Laura Z. Rassenti, Ph.D., Fitzgerald S. Lao, B.S., Rommel Tawatao, B.S., Stefan Weigland, PhD, Charles Prussak, PhD, Dennis A. Carson, MD, Thomas J. Kipps, M.D., Ph.D

Blood (2011) 118 (21): 927.

https://doi.org/10.1182/blood.V118.21.927.927

Published: 2011

Journal Articles

Targeting of Chronic Lymphocytic Leukemia B Cells with a Novel Monoclonal Antibody to ROR1

Bing CUi, PhD, George F. Widhopf, II, PhD, Jian Yu, PhD, Daniel Martinez, BS, Esther Avery, B.S., Suping Zhang, PhD, Liguang Chen, MD, PhD, Rongrong Wu, Christina C.N. Wu, Ph.D., Charles Prussak, PhD, Thomas J. Kipps, M.D., Ph.D

Blood (2011) 118 (21): 984.

https://doi.org/10.1182/blood.V118.21.984.984

Published: 2011

Journal Articles

Heat Shock Protein 90 (Hsp90) Activity Status Is An Independent Prognostic Marker in Chronic Lymphocytic Leukemia (CLL) and Correlates with IgV H Mutational Status, ZAP-70 Expression and Time to First Treatment

Januario E. Castro, M.D., Juan S. Barajas-Gamboa, M.D., Julio A. Diaz-Perez, M.D., M.S., Lina M. Ariza-Serrano, M.D. (c), Johanna Melo-Cardenas, B.Sc, Mauricio Rodriguez, D.D.S., M.S., Mauricio Urquiza, Ph.D., Thomas J. Kipps, M.D., Ph.D

Blood (2011) 118 (21): 2544.

https://doi.org/10.1182/blood.V118.21.2544.2544

Published: 2011

Journal Articles

Increased Activity of Aldehyde Dehydrogenase, a Stem/Progenitor Cell Marker, in Chronic Lymphocytic Leukemia,

Raymond P. Wu, Ph.D., Christina C.N. Wu, Ph.D., Tomoko Hayashi, M.D., Ph.D., Laura Z. Rassenti, Ph.D., Thomas J. Kipps, M.D., Ph.D, Dennis A. Carson, M.D.

Blood (2011) 118 (21): 3867.

https://doi.org/10.1182/blood.V118.21.3867.3867

Published: 2011

Journal Articles

Treatment of Chronic Lymphocytic Leukemia Patients with Lenalidomide Induces Down-Regulation of miR342-3p Associated with Over-Expression of Tumor Suppressor RASSF4,

Emanuela M. Ghia, PhD, Lillian Werner, Danelle F. James, M.D., Donna Neuberg, ScD, Laura G Corral, Senior, Scientist, Laura Z. Rassenti, Ph.D., Carlo M. Croce, MD, Thomas J. Kipps, M.D., Ph.D

Blood (2011) 118 (21): 3885.

https://doi.org/10.1182/blood.V118.21.3885.3885

Published: 2011

Journal Articles

Relative Prognostic Significance of ZAP-70 and IGHV1-69 Expression in Chronic Lymphocytic Leukemia,

Laura Z. Rassenti, Ph.D., Emanuela M. Ghia, PhD, Lillian Werner, Donna Neuberg, ScD, George F. Widhopf, II, PhD, Thomas J. Kipps, M.D., Ph.D

Blood (2011) 118 (21): 3891.

https://doi.org/10.1182/blood.V118.21.3891.3891

Published: 2011

Journal Articles

Improved Outcome in Unrelated Donor Recipients After Allogeneic Hematopoietic Stem Cell Transplantation for Patients with Advanced Relapse / Refractory Chronic Lymphocytic Leukemia

Januario E. Castro, M.D., Juan S. Barajas-Gamboa, M.D., Julio A. Diaz-Perez, M.D., M.S., Lina M. Ariza-Serrano, M.D. (c), Sue Corringham, R.N., Thomas J. Kipps, M.D., Ph.D, Edward D. Ball, M.D.

Blood (2011) 118 (21): 4474.

https://doi.org/10.1182/blood.V118.21.4474.4474

Published: 2011

Journal Articles

Eradication of Minimal Residual Disease Using Alemtuzumab Consolidation After High-Dose Methyl-Prednisolone Plus Rituximab (HDMP-R) Is Safe, Effective and Induces Long Term Remission in Chronic Lymphocytic Leukemia

Januario E. Castro, M.D., Lina M. Ariza-Serrano, M.D. (c), Juan S. Barajas-Gamboa, M.D., Julio A. Diaz-Perez, M.D., M.S., Danelle F. James, M.D., Amine Ale-Ali, Pharm.D., Thomas J. Kipps, M.D., Ph.D

Blood (2011) 118 (21): 2866.

https://doi.org/10.1182/blood.V118.21.2866.2866

Published: 2011

Journal Articles

Lenalidomide and Rituximab for the Initial Treatment of Patients with Chronic Lymphocytic Leukemia (CLL) A Multicenter Study of the CLL Research Consortium

Danelle F. James, M.D., Jennifer R. Brown, MD, PhD, Lillian Werner, William G. Wierda, MD, PhD, Jaqueline C. Barrientos, MD, Januario Castro, MD, Andrew Greaves, Laura Z. Rassenti, Ph.D., Kanti R. Rai, MD, Donna Neuberg, ScD, Thomas J. Kipps, M.D., Ph.D

Blood (2011) 118 (21): 291.

https://doi.org/10.1182/blood.V118.21.291.291

Published: 2011

Journal Articles

Chronic Lymphocytic Leukemia Patients with IGHV Genes Carrying Only Silent Mutations Have A Longer Time From Diagnosis to Initial Therapy Than Patients Expressing B-Cell Receptors with No Somatic Mutations

Matthew Kaufman, MD, Xiao J. Yan, MD, PhD, Emanuela M. Ghia, PhD, Donna Neuberg, ScD, Laura Z. Rassenti, Ph.D., Kostas Stamatopoulos, MD, Paolo Ghia, MD, PhD, David G Oscier, MD, Frederic Davi, MD, PhD, Richard Rosenquist, MD, PhD, Chrysoula Belessi, MD, Zadie Davis, PhD, Andreas Agathangelidis, Neil Kay, MD, John C. Byrd, MD, Jennifer R Brown, MD, PhD, Kanti R. Rai, M.D., Thomas J. Kipps, M.D., Ph.D, Nicholas Chiorazzi, M.D.

Blood (2011) 118 (21): 288.

https://doi.org/10.1182/blood.V118.21.288.288

Published: 2011

Journal Articles

In Vitro Propagation of Mesenchymal Stromal Cells From Marrow Aspirates of Patients with Chronic Lymphocytic Leukemia Is Dependent Upon Physiologic Oxygen Tension

Jessie-Farah Fecteau, Ph.D., Davorka Messmer, PhD, Suping Zhang, PhD, Bing Cui, PhD, Liguang Chen, MD, PhD, Thomas J. Kipps, M.D., Ph.D

Blood (2011) 118 (21): 2839.

https://doi.org/10.1182/blood.V118.21.2839.2839

Published: 2011

Journal Articles

MicroRNA Profiling in Patients with CLL B Cells Expressing the Unmutated IGHV1-69 Gene

Laura Z. Rassenti, Ph.D., Emanuela M. Ghia, PhD, Lillian Werner, Donna Neuberg, ScD, Muller Fabbri, MD, Stefano Volinia, PhD, George F. Widhopf, II, PhD, Carlo M. Croce, MD, Thomas J. Kipps, M.D., Ph.D

Blood (2011) 118 (21): 2846.

https://doi.org/10.1182/blood.V118.21.2846.2846

Published: 2011

Journal Articles

Efficient Gene Delivery to Chronic Lymphocytic Leukemia (CLL) Cells with Microbubbles Bearing ROR1 Antibody

Suping Zhang, PhD, Wenjin Cui, PhD, Robert Mattrey, MD, Thomas J. Kipps, M.D., Ph.D

Blood (2011) 118 (21): 2857.

https://doi.org/10.1182/blood.V118.21.2857.2857

Published: 2011

Journal Articles

Ad-ISF35-Transduced Autologous Cells In Combination with Fludarabine, Cyclophosphamide, Rituximab (FCR) Induces Complete and Partial Responses In a Phase 1b Study for Patients with Fludarabine-Refractory and/or Del(17p)/p53-Defective Chronic Lymphocytic Leukemia (CLL)

Januario E. Castro, M.D., Lee Schwartzberg, MD, FACP, Javier Pinilla-Ibarz, MD, PhD, Johanna Melo-Cardenas, B.Sc, Juan S. Barajas-Gamboa, M.D., Mark J. Cantwell, PhD, Thomas J. Kipps, M.D., Ph.D

Blood (2011) 118 (21): 168.

https://doi.org/10.1182/blood.V118.21.168.168

Published: 2011

NARROW

Low Expression of ROR1 on Chronic Lymphocytic Leukemia Is Associated with Other Atypical Findings

Variation in Health-Related Quality of Life by ECOG Performance Status and Fatigue Among Patients with Chronic Lymphocytic Leukemia

Variation in Health-Related Quality of Life by Age Among Patients with Chronic Lymphocytic Leukemia

Navitoclax (ABT-263) Plus Fludarabine/Cyclophosphamide/Rituximab (FCR) or Bendamustine/Rituximab (BR): A Phase 1 Study in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL),

ROR1 Expression Accelerates Leukemia Development in RORxTCL1 Transgenic Mice,

Mir-155 Contributed to Chronic Lymphocytic Leukemia Survival by Modulation of BCR-Signalling

A Monoclonal Antibody Specifically Targeting CD44 Inhibits B-Cell Chronic Lymphocytic Leukemia Cell Survival In Vitro and In Vivo

Targeting of Chronic Lymphocytic Leukemia B Cells with a Novel Monoclonal Antibody to ROR1

Heat Shock Protein 90 (Hsp90) Activity Status Is An Independent Prognostic Marker in Chronic Lymphocytic Leukemia (CLL) and Correlates with IgV H Mutational Status, ZAP-70 Expression and Time to First Treatment

Increased Activity of Aldehyde Dehydrogenase, a Stem/Progenitor Cell Marker, in Chronic Lymphocytic Leukemia,

Treatment of Chronic Lymphocytic Leukemia Patients with Lenalidomide Induces Down-Regulation of miR342-3p Associated with Over-Expression of Tumor Suppressor RASSF4,

Relative Prognostic Significance of ZAP-70 and IGHV1-69 Expression in Chronic Lymphocytic Leukemia,

Improved Outcome in Unrelated Donor Recipients After Allogeneic Hematopoietic Stem Cell Transplantation for Patients with Advanced Relapse / Refractory Chronic Lymphocytic Leukemia

Eradication of Minimal Residual Disease Using Alemtuzumab Consolidation After High-Dose Methyl-Prednisolone Plus Rituximab (HDMP-R) Is Safe, Effective and Induces Long Term Remission in Chronic Lymphocytic Leukemia

Lenalidomide and Rituximab for the Initial Treatment of Patients with Chronic Lymphocytic Leukemia (CLL) A Multicenter Study of the CLL Research Consortium

Chronic Lymphocytic Leukemia Patients with IGHV Genes Carrying Only Silent Mutations Have A Longer Time From Diagnosis to Initial Therapy Than Patients Expressing B-Cell Receptors with No Somatic Mutations

In Vitro Propagation of Mesenchymal Stromal Cells From Marrow Aspirates of Patients with Chronic Lymphocytic Leukemia Is Dependent Upon Physiologic Oxygen Tension

MicroRNA Profiling in Patients with CLL B Cells Expressing the Unmutated IGHV1-69 Gene

Efficient Gene Delivery to Chronic Lymphocytic Leukemia (CLL) Cells with Microbubbles Bearing ROR1 Antibody

Ad-ISF35-Transduced Autologous Cells In Combination with Fludarabine, Cyclophosphamide, Rituximab (FCR) Induces Complete and Partial Responses In a Phase 1b Study for Patients with Fludarabine-Refractory and/or Del(17p)/p53-Defective Chronic Lymphocytic Leukemia (CLL)

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only